Mail

BCLI - Brainstorm Cell Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

3.9900

-0.0700 (-1.72%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	4.0600
Open	4.1300
Bid	3.9500 x 900
Ask	4.0000 x 2900
Day's Range	3.9000 - 4.1300
52 Week Range	2.9200 - 4.5000
Volume	90,614
Avg. Volume	57,909

Market Cap	86.595M
Beta (3Y Monthly)	0.85
PE Ratio (TTM)	N/A
EPS (TTM)	-0.8150
Earnings Date	Jul 22, 2019 - Jul 26, 2019
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	10.50

Trade prices are not sourced from all markets

All

News

Press Releases

Simply Wall St.10 days ago
If You Had Bought Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Three Years Ago, You Could Pocket A 59% Gain Today
One simple way to benefit from the stock market is to buy an index fund. But many of us dare to dream of bigger...
GlobeNewswire18 days ago
Third Clinical Site Initiated for BrainStorm Cell Therapeutic’s Phase 2 Progressive MS Study
NEW YORK, July 02, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
GlobeNewswire2 months ago
BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting
NEW YORK and SEATTLE, May 31, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
GlobeNewswire2 months ago
BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study
NEW YORK, May 30, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
GlobeNewswire2 months ago
BrainStorm Senior Management to Present at BIO 2019
- Chaim Lebovits, President & CEO Corporate Presentation, June 4, 2019 - - Ralph Kern MD, MHSc, Chief Medical Officer & Chief Operating Officer Round Table Panelist,.
Zacks Small Cap Research2 months ago
BCLI: Enrollment in Phase 3 ALS Trial to Complete in 3Q19…
During the 71st American Academy of Neurology (AAN), BrainStorm Cell Therapeutics, Inc. (BCLI) presented two scientific abstracts that provided a detailed molecular characterization of neurotrophic factor production by NurOwn® and a correlation between cerebrospinal fluid biomarkers and clinical improvement in the Phase 2 ALS study. The following radar plot shows the fold change in the secretion of various neurotrophic factors (NTFs) by MSC-NTF compared to MSC, which varied from 2x to 9x for the tested NTFs.
GlobeNewswire2 months ago
BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London
NEW YORK and LONDON, May 13, 2019 -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases,.
GlobeNewswire2 months ago
BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update
Highlights Scientific Advances and Continued Progress in NurOwn® ALS Phase 3 Trial and Progressive MS Phase 2 Trial; Expansion of the proprietary cellular technology.
GlobeNewswire3 months ago
BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases
NEW YORK, April 30, 2019 -- Brainstorm-Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today.
Zacks Small Cap Research4 months ago
BCLI: Two Abstracts to be Presented at AAN Annual Meeting…
On March 28, 2019, BrainStorm Cell Therapeutics, Inc. (BCLI) announced that two abstracts have been selected for presentation at the 71st American Academy of Neurology (AAN) Annual Meeting, which is being held May 4-10, 2019. The presentations focus on biomarker correlations with clinical outcomes in the phase 2 study and the genetic characterization of neurotrophic factor production in NurOwn®, one of which was selected for oral presentation during the ‘Emerging Science Session’. On March 13, 2019, BrainStorm Cell Therapeutics, Inc. (BCLI) held a conference call to announce that the Israeli Ministry of Health has approved the company’s application for the Hospital Exemption (HE) program, which will allow for the treatment of 13 amyotrophic lateral sclerosis (ALS) patients with NurOwn®.
GlobeNewswire4 months ago
Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting
NEW YORK, March 28, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
GlobeNewswire4 months ago
BrainStorm Announces Grant of an additional New European Patent for NurOwn®
NEW YORK, March 26, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today.
GlobeNewswire4 months ago
Atlas Blockchain Announces Definitive Agreement for the Acquisition of Isracann and Amendment to Investor Services Agreement
Atlas Blockchain Group Inc. (CSE:AKE) (A49.F) (ATLEF) (the “Company” or “Atlas”) is pleased to announce, further to its news release on October 11, 2018, the Company has entered into a definitive share exchange agreement dated March 12, 2019 (the “Share Exchange Agreement”), pursuant to which the Company has agreed to acquire all of the issued and outstanding common shares (the “Isracann Shares”) in the capital of Isracann Biosciences Inc. (“Isracann”), a private British Columbia company, from the shareholders of Isracann (the “Isracann Shareholders”), subject to the conditions set out in the Share Exchange Agreement (the “Transaction”).
Zacks Small Cap Research4 months ago
BCLI: Hospital Exemption Approved in Israel; First Patient Enrolled in Phase 2 Study in Progressive MS…
On March 13, 2019, BrainStorm Cell Therapeutics, Inc. (BCLI) held a conference call to announce that the Israeli Ministry of Health has approved the company’s application for the Hospital Exemption (HE) program, which will allow for the treatment of 13 amyotrophic lateral sclerosis (ALS) patients with NurOwn®. The patients to be treated were selected based on separate inclusion/exclusion criteria than is being used for the ongoing Phase 3 trial of NurOwn® in ALS. BrainStorm is continuing to enroll patients in the Phase 3 clinical trial of NurOwn® (NCT03280056) for the treatment of ALS.
GlobeNewswire4 months ago
BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
NEW YORK and CLEVELAND, March 14, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly.
Simply Wall St.4 months ago
Breakeven On The Horizon For Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Brainstorm Cell Therapeutics Inc.'s (NASDAQ:BCLI): Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to addressRead More...
Benzinga4 months ago
The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 11) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...
GlobeNewswire4 months ago
BrainStorm to Host Business Update Conference Call
NEW YORK, March 07, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
GlobeNewswire5 months ago
BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study
NEW YORK and CLEVELAND, Feb. 22, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly.
GlobeNewswire5 months ago
BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland
ZURICH, Switzerland and NEW YORK, Feb. 21, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly.
GlobeNewswire5 months ago
BrainStorm Issues a Statement to Patients and Shareholders
Brainstorm stays fully committed to advance our pivotal phase 3 ALS trial towards a BLA submission. We strongly believe that currently this is the best and most credible pathway to demonstrate that NurOwn® may be a safe and an effective treatment option for ALS patients. If the outcome of the trial is successful, we hope to be able to bring a much-needed solution to ALS patients as quickly as possible.
GlobeNewswire5 months ago
BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium
NEW YORK, Feb. 04, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
GlobeNewswire6 months ago
BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida
NEW YORK, Jan. 25, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
GlobeNewswire6 months ago
BrainStorm Granted Additional Patent for NurOwn® in Israel
NEW YORK, Jan. 22, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative.
GlobeNewswire6 months ago
BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA
NEW YORK and IRVINE, Calif., Jan. 11, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly.